Clear Investment Research’s AbbVie ABBV Stock Holding History

Clear Investment Research’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-279	Closed	-$60.6K	–	58
2026 Q1	$60.6K	Buy	+279	New	+$61.9K	0.09%	99
2025 Q4	–	Sell	-278	Closed	-$64.5K	–	52
2025 Q3	$64.5K	Buy	278 +25	+10%	+$5.09K	0.09%	105
2025 Q2	$47.1K	Hold	253	–	–	0.06%	114
2025 Q1	$53.1K	Hold	253	–	–	0.07%	106
2024 Q4	$45.1K	Hold	253	–	–	0.06%	112
2024 Q3	$50.1K	Hold	253	–	–	0.07%	106
2024 Q2	$43.5K	Buy	253 +2	+0.8%	+$331	0.06%	105
2024 Q1	$45.7K	Sell	251 -59	-19%	-$10.2K	0.06%	105
2023 Q4	$48K	Buy	+310	New	+$45.2K	0.07%	107
2019 Q4	–	Sell	-10	Closed	-$1K	–	109
2019 Q3	$1K	Buy	10 +3	+43%	+$206	﹤0.01%	132
2019 Q2	$1K	Hold	7	–	–	﹤0.01%	132
2019 Q1	$1K	Hold	7	–	–	﹤0.01%	129
2018 Q4	$1K	Hold	7	–	–	﹤0.01%	123
2018 Q3	$1K	Buy	+7	New	+$664	﹤0.01%	133

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clear Investment Research's ABBV Position: Q2 2026 in Review

Clear Investment Research sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 279 shares — an estimated $60.6K sold.

Clear Investment Research first reported a position in ABBV in Q3 2018 and held it in 14 quarters. The position peaked at $64.5K in Q3 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Clear Investment Research reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Clear Investment Research sold 279 AbbVie shares in Q2 2026, an estimated $60.6K.
Clear Investment Research first reported a position in AbbVie in Q3 2018 and held it in 14 quarters.
Clear Investment Research's AbbVie position peaked at $64.5K in Q3 2025.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clear Investment Research's 13F filing for Q2 2026, filed 11 Aug 2026.